Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Amgen, Inc.

Advancing Toward Expanded Precision Treatment of KRAS-Mutated Lung, Colorectal, and Other Solid Tumors

Release Date: August 23, 2021
Expiration Date: August 23, 2022

Activity Overview

This online activity features a panel of experts discussing the latest clinical trial findings and guideline recommendations for patients with KRAS-mutated solid tumors. Faculty experts present recent efficacy data on novel drug therapies targeting KRAS-mutated non-small lung cell carcinoma and colorectal cancer and discuss how recent advances in KRAS-specific therapies will impact the treatment of patients with KRAS-mutated solid tumors.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and pathologists who treat patients with cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with cancer will be invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe the mechanism of action of KRAS-targeted therapy in the context of KRAS-mutated tumor biology
  • Assess current and future applications of molecular testing strategies used to identify KRAS mutations across solid tumors
  • Evaluate efficacy and safety data from recent clinical trials investigating novel therapies for the management of KRAS-mutated solid tumors
  • Apply ongoing clinical trial inclusion criteria and emerging data to clinical scenarios for patients with KRAS-mutated solid tumors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Clinical Research
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant research support: Novartis, Pfizer, Takeda, Roche, Merck & Co, Mirati Therapeutics; Consultant: Merck & Co. (uncompensated).

Ramaswamy Govindan, MD
Ramaswamy Govindan, MD
Department of Medicine
Anheuser Busch Chair in Medical Oncology
Section of Medical Oncology
Division of Oncology
Washington University School of Medicine
St Louis, MO

Disclosures: Consultant: Pfizer, Merck & Co, Boehringer lngelheim, Clovis, Helsinn Therapeutics, Genentech, AbbVie, GlaxoSmithKline, Celgene, lnivata.

Vamsidhar Velcheti, MD
Vamsidhar Velcheti, MD
Associate Professor
Department of Medicine
New York University Grossman School of Medicine
Thoracic Med Oncology Program
Perlmutter Cancer Center
New York University Langone Health
New York, NY

Disclosures: Grant research support: Merck & Co, AstraZeneca, Turning Point Therapeutics, Calthera Biosciences, Alkermes, Biodesix, Novartis, Ivygen, Dracen Pharmaceuticals, Amgen, Bristol Myers Squibb, Cullinan Oncology; Consultant: Merck & Co, AstraZeneca, Novartis, Foundation Medicine, Bristol Myers Squibb, Novocure, EMD Serono, Amgen, Elli Lilly and Company.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By